Glenmark Life Sciences Ltd

Alivus Life Sciences Ltd (formerly Glenmark Life Sciences) reported a 6.9% YoY increase in revenue for FY26, reaching ₹25,518 Mn. EBITDA grew by 19.6% YoY to ₹8,577 Mn, with margins at 33.6%. PAT stood at ₹5,645 Mn, up 16.2% YoY. Q4FY26 revenue grew by 6.1% YoY to ₹6,891 Mn, with EBITDA at ₹2,373 Mn, up 13.8% YoY. The company generated a strong free cash flow of ₹2,590 Mn, with cash and equivalents at ₹7,824 Mn as of March 31, 2026. The CDMO business saw an 18% YoY growth in the second half of the year.

Alivus Life Sciences Ltd. announced audited financial results for the quarter and year ended March 31, 2026. The Board approved these results on May 14, 2026, and recommended a final equity dividend of ₹5 (250%) per share, subject to shareholder approval. For FY26, the company reported revenue from operations of ₹25,518.32 million and a profit after tax of ₹5,644.83 million. The Board meeting commenced at 4.45 p.m. and concluded at 6.15 p.m.

Alivus Life Sciences Ltd's Board of Directors approved the audited financial results for the quarter and year ended March 31, 2026. The company reported revenue from operations of ₹25,518.32 million and a profit after tax of ₹5,644.83 million for the year ended March 31, 2026. The board also recommended a final equity dividend of ₹5 (250%) per equity share of ₹2 each, subject to shareholder approval. The meeting concluded at 6.15 p.m.

Alivus Life Sciences Ltd. announced the closure of its trading window from April 1, 2026, to May 16, 2026, for designated persons. This closure is in anticipation of the Board of Directors meeting on May 14, 2026, to approve the audited financial results for the quarter and year ended March 31, 2026, and to consider recommending a dividend on equity shares.

Alivus Life Sciences Ltd has scheduled a Board of Directors meeting on May 14, 2026, to consider and approve the audited financial results for the quarter and year ended March 31, 2026. The board will also consider recommending a dividend on equity shares for the same period. The company has announced a trading window closure for designated persons from April 01, 2026, to May 16, 2026, for the purpose of approving the audited financial results.

Alivus Life Sciences Ltd. has received an order from the Income Tax Department, Faceless Assessment Unit, under Section 143(1) read with Section 144B of the Income Tax Act, 1961, dated 20th March, 2026. The order pertains to the Assessment Year 2023-24 (Financial Year 2022-23) and includes a tax demand of Rs. 2,60,67,810 on account of disallowances of expenditure under Section 37(1). The company has stated that there is no material impact on financial activities, no impact on operations, or other activities of the company due to the intimation of tax payable. The order is currently appealable before the appellate authority and the company will make an assessment to exercise the right to appeal.

Alivus Life Sciences Ltd, in compliance with the Obligations and Disclosure Requirements) Regulations, 2015, as amended ('SEBI Listin Regulations'), has informed about a fire incident that occurred on February 14, 2026, at their manufacturing facility in Dahej, Bharuch district, Gujarat. The incident was confined to one production block, affecting a portion of the intermediate manufacturing facilities, while the Active Pharmaceutical Ingredient (API) manufacturing facilities remained unaffected. The situation has been assessed and the company expects to resume API production from March 1, 2026, and intermediate production from mid-March 2026. This temporary cessation of manufacturing operations will result in delayed shipments. Alivus Life Sciences emphasizes safety and follows stringent safety standards and protocols across its operations.

On Saturday, February 14, 2026, a fire broke out at Alivus Life Sciences' API Plant located in Dahej, Gujarat, India. The incident resulted in three injuries and was brought under control within an hour. The company is currently investigating the cause and assessing the damage. Adequate insurance coverage is in place, and the insurance companies have been informed. The company is committed to maintaining the highest safety standards.

Alivus Life Sciences Limited, a leading developer and manufacturer of select, high-value, non-commoditized, Active Pharmaceutical Ingredients (APIs) in chronic therapeutic areas, announced its financial results for the quarter and nine months ended December 31, 2025. The company reported record revenues of Rs. 6,729 Mn for Q3FY26, a growth of 14.4% QoQ and 4.8% YoY. EBITDA was at Rs. 2,452 Mn, a growth of 26.5% QoQ and 22.1% YoY. EBITDA margins were at a record high of 36.4%, up 340 bps QoQ and 510 bps YoY. PAT for Q3FY26 stood at Rs. 1,503 Mn, a growth of 15.5% QoQ and 9.7% YoY. The company generated a strong free cash flow of Rs. 2,207 Mn leading to Cash and Cash Equivalents of Rs. 7,330 Mn as of December 31, 2025. The performance was led by a favourable product mix, strong recovery in the CDMO business, increased contributions from new product launches, and continued gains in operational efficiency.

Alivus Life Sciences Ltd, formerly known as Glenmark Life Sciences Ltd, announced its unaudited financial results for the third quarter and nine months ended December 31, 2025. The company's revenue from operations stands at 6,868.17 million, with a total income of 6,523.00 million. The total expenses amounted to 2,876.16 million, resulting in a profit before tax of 19,003.48 million. The earnings per equity share (Face Value of = 2/- each) are (a) Basic (in 2) and (b) Diluted (in =). The company's paid-up equity share capital is 13,391.81 million, with other equity excluding revaluation reserve.